18 September 2017

Gates invests in Immunocore

The Bill & Melinda Gates Foundation is investing up to $40 million in Immunocore to spur research into the use of T cell receptor (TCR)-based therapeutics to treat tuberculosis and HIV. Both programs are in preclinical stages, but Immunocore has generated data to support the idea of using TCR-based therapeutics to treat infectious diseases. Last year, Immunocore released in vitro data showing its molecules turn the immune system against HIV-infected CD4+ T-cells, suggesting they may be able to wipe out reactivated HIV reservoir cells. Source: Fierce Biotech 18/9/2017

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).